Use of nitrogen and potassium reserves during growth of grape vine cuttings

Single node cuttings of dormant grape vine canes were analysed to determine the relative amounts of soluble and insoluble nitrogen, and of potassium that are stored in bark and wood and in node and internode respectively. The amounts of these constituents that can be utilized for the growth of new shoot and roots were determined in experiments in which cuttings were grown in nutrient solutions which were either complete or lacking in nitrogen or potassium. When cuttings were grown for ten weeks with no added nitrogen 87 percent of the soluble nitrogen and 43 percent of the insoluble nitrogen was utilized for new growth. When cuttings were grown with an unrestricted supply of fertilizer nitrogen 82 percent of the soluble nitrogen and 20 percent of the insoluble nitrogen was utilized for new growth during the same period. Even in vines adequately supplied with fertilizer nitrogen, stored nitrogen of the cane is used preferentially for new growth.Vine cuttings grown for ten weeks with no supplemental potassium utilized 48 percent of the potassium reserve in the dormant cane for the growth of new shoot and roots. The amount translocated to the shoots was five times the amount transferred to roots. When supplemental potassium was supplied in the nutrient solution the potassium level in plant canes (initial cutting) was increased relative to that in the original cutting with equal amounts being translocated to both shoots and roots. It would appear that in contrast to nitrogen, stored potassium is not used preferentially for the growth of new shoot and roots.Die Nutzung von Stickstoff- und Kaliumreserven beim Wachstum von RebstecklingenEinaugenstecklinge von Rebenholz, das sich in der Ruhephase befand, wurden analysiert, um die relativen Mengen von löslichem und unlöslichem Stickstoff und von Kalium zu bestimmen, die im Rinden- und Holzteil bzw. Nodus und Internodium eingelagert waren. In Nährlösungen, die entweder vollständig waren oder in denen N oder K fehlten, wurden Stecklinge angezogen und an ihnen ermittelt, in welchem Ausmaß diese Elemente für das Wachstum neuer Sprosse und Wurzeln genutzt wurden.Wuchsen die Stecklinge 10 Wochen lang ohne zusätzlichen Stickstoff, so wurden 87% des löslichen und 43% des unlöslichen Stickstoffs für das neue Wachstum genutzt. Bei unbeschränktem Vorrat an Düngerstickstoff wurden 82% des löslichen und 20% des unlöslichen Stickstoffs für das neue Wachstum während derselben Periode genutzt. Selbst in Reben, die ausreichend mit Dünger-Stickstoff versorgt waren, wurde vorzugsweise der im Holz eingelagerte Stickstoff für das neue Wachstum verwendet. Rebstecklinge, die 10 Wochen lang ohne zusätzliches Kalium wuchsen, nutzten 48% der Kalium-Reserve in dem ruhenden Rebholz für die Entwicklung neuer Sprosse und Wurzeln. In die Sprosse wurde fünf mal so viel Kalium wie in die Wurzeln befördert. Nach einem Kalium-Zusatz zur Nährlösung stieg der Kaliumgehalt im Stecklingsholz (Ausgangsholz) gegenüber dem im Ausgangsstück, wobei gleiche Mengen in Sprosse und Wurzeln befördert wurden. Es hat den Anschein, als ob bei der Bildung neuer Sprosse und Wurzeln das eingelagerte Kalium - im Gegensatz zum Stickstoff - nicht bevorzugt verwertet würde

Regional investigation of a cyclosporiasis outbreak linked to imported romaine lettuce – Nebraska and Iowa, June–August 2013

A regional, multistate investigation into a June–August 2013 cyclosporiasis outbreak was conducted in Nebraska, Iowa, and neighbouring states. Cases were confirmed on the basis of laboratory and clinical findings. Of 227 cases in Iowa (n = 140) and Nebraska (n=87) residents, 162 (71%) reported dining at chain A/B restaurants – 96% reported house salad consumption. A case-control study identified chain A/B house salad as the most likely vehicle. Traceback was conducted to ascertain production lot codes of bagged salad mix (iceberg and romaine lettuce, red cabbage, and carrots) served as house salad in implicated restaurants. A single production lot code of salad mix supplied by both a common producer and distributor was linked to the majority of confirmed cases in persons reporting regional chain A/B exposure. The salad mix linked to illnesses contained imported romaine lettuce from two separate single-grower fields-of-origin and 51 additional field from another grower

Yield and costs of molecular diagnostics on thyroid cytology slides in the Netherlands, adapting the Bethesda classification

Objective To evaluate our institutional experience with molecular diagnostics (MD) on thyroid cytology smears, evaluate the costs and describe MD guided clinical management of indeterminate Bethesda III/V thyroid nodules. Methods We performed a retrospective review of 164 Bethesda III or V thyroid cytopathology reports subjected to MD from 2013 to 2020, that altered Bethesda classification or management. MD consisted of mutation and gene fusion analysis by next-generation sequencing (NGS) of morphologically analysed and selected cytological slides. Findings were modelled to nationwide data on Bethesda incidences from 'the Dutch Pathology Registry' PALGA, and costs were estimated. Results 82 of 164 cases received an upgrade in Bethesda class. Twenty cases changed from Bethesda III to IV/V, 62 from Bethesda III or V to VI, and 72 remained unaltered. We estimate net savings with implementing MD, by preventing 454 repeat cytology and 326 (diagnostic) hemithyroidectomies, to be at least 2 million Euro annually in the Netherlands. Per Bethesda III and V patient, net savings would be about 100 Euro and 4100 Euro, respectively. Conclusion NGS-based MD on nucleic acids extracted directly from cytology slides is a feasible and cost saving tool for personalized management in indeterminate Bethesda III/V thyroid cytology. Based on the interpretation of our retrospective data, we assume that this approach results in less disease burden for the patient, reduced surgical interventions and complication risks, reduced sick leave, among others. Further evaluation of structural implementation of the presented approach in routine thyroid Bethesda III/V cytology in a prospective setting is warranted.MTG3 - Moleculaire genetica en pathologie van endocriene tumorenMolecular tumour pathology - and tumour genetic

Contrasting effects of diclofenac and ibuprofen on active imatinib uptake into leukaemic cells

BACKGROUND: The human organic cation transporter-1 (OCT-1) is the primary active protein for imatinib uptake into target BCR-ABL-positive cells. Non-steroidal anti-inflammatory drugs (NSAIDs) are frequently used by chronic myeloid leukaemia (CML) patients on imatinib to manage musculoskeletal complaints. METHODS: Here we investigated the impact of NSAIDs on functional activity of the OCT-1 (OCT-1 activity; OA) in CML cells. RESULTS: Although ten of twelve NSAIDs tested had no significant impact on OA (P>0.05), we observed increased OA (27% increase in K562; 22% increase in KU812 cells, P<0.05) and reduced IC50(imatinib) when treated with diclofenac. Co-incubation with imatinib and diclofenac resulted in a significantly lower viable cell number compared with imatinib alone. In contrast, ibuprofen led to a significant decrease in OA, an increase in IC50(imatinib) and thus reduced the cytotoxicity of imatinib. In primary CML samples, diclofenac significantly increased OA, particularly in patients with low OA (<4 ng per 200 000 cells), and significantly decreased IC50(imatinib). Ibuprofen induced significant decreases in OA in CML samples and healthy donors. CONCLUSION: On the basis of the expected impact of these two drugs on OA, ibuprofen should be avoided in combination with imatinib. Further studies are warranted regarding the potential benefit of diclofenac to improve OA in a clinical setting.J. Wang, T.P. Hughes, C.H. Kok, V.A. Saunders, A. Frede, K. Groot-Obbink, M. Osborn, A.A. Somogyi, R.J. D’Andrea and D.L. Whit

The Movember Foundation's GAP3 cohort: a profile of the largest global prostate cancer active surveillance database to date

OBJECTIVES: The Movember Foundation launched the Global Action Plan Prostate Cancer Active Surveillance (GAP3) initiative to create a global consensus on the selection and monitoring of men with low‐risk prostate cancer (PCa) on active surveillance (AS). The aim of this study is to present data on inclusion and follow‐up for AS in this unique global AS database. PATIENTS AND METHODS: Between 2014 and 2016, the database was created by combining patient data from 25 established AS cohorts worldwide (USA, Canada, Australasia, UK and Europe). Data on a total of 15 101 patients were included. Descriptive statistics were used to report patients' clinical and demographic characteristics at the time of PCa diagnosis, clinical follow‐up, discontinuation of AS and subsequent treatment. Cumulative incidence curves were used to report discontinuation rates over time. RESULTS: At diagnosis, the median (interquartile range [IQR]) patient age was 65 (60–70) years and the median prostate‐specific antigen level was 5.4 (4.0–7.3) ng/mL. Most patients had clinical stage T1 disease (71.8%), a biopsy Gleason score of 6 (88.8%) and one tumour‐positive biopsy core (60.3%). Patients on AS had a median follow‐up time of 2.2 (1.0–5.0) years. After 5, 10 and 15 years of follow‐up, respectively, 58%, 39% and 23% of patients were still on AS. The current version of GAP3 has limited data on magnetic resonance imaging (MRI), quality of life and genomic testing. CONCLUSIONS: GAP3 is the largest worldwide collaboration integrating patient data from men with PCa on AS. The results will allow individual patients and clinicians to have greater confidence in the personalized decision to either delay or proceed with active treatment. Longer follow‐up and the evaluation of MRI, new genomic markers and patient‐related outcomes will result in even more valuable data and eventually in better patient outcomes

The Movember Foundation&apos;s GAP3 cohort : a profile of the largest global prostate cancer active surveillance database to date

Objectives: The Movember Foundation launched the Global Action Plan Prostate Cancer Active Surveillance (GAP3) initiative to create a global consensus on the selection and monitoring of men with low-risk prostate cancer (PCa) on active surveillance (AS). The aim of this study is to present data on inclusion and follow-up for AS in this unique global AS database. Patients and Methods: Between 2014 and 2016, the database was created by combining patient data from 25 established AS cohorts worldwide (USA, Canada, Australasia, UK and Europe). Data on a total of 15 101 patients were included. Descriptive statistics were used to report patients' clinical and demographic characteristics at the time of PCa diagnosis, clinical follow-up, discontinuation of AS and subsequent treatment. Cumulative incidence curves were used to report discontinuation rates over time. Results: At diagnosis, the median (interquartile range [IQR]) patient age was 65 (60\u201370) years and the median prostate-specific antigen level was 5.4 (4.0\u20137.3) ng/mL. Most patients had clinical stage T1 disease (71.8%), a biopsy Gleason score of 6 (88.8%) and one tumour-positive biopsy core (60.3%). Patients on AS had a median follow-up time of 2.2 (1.0\u20135.0) years. After 5, 10 and 15 years of follow-up, respectively, 58%, 39% and 23% of patients were still on AS. The current version of GAP3 has limited data on magnetic resonance imaging (MRI), quality of life and genomic testing. Conclusions: GAP3 is the largest worldwide collaboration integrating patient data from men with PCa on AS. The results will allow individual patients and clinicians to have greater confidence in the personalized decision to either delay or proceed with active treatment. Longer follow-up and the evaluation of MRI, new genomic markers and patient-related outcomes will result in even more valuable data and eventually in better patient outcomes

Ezekiel Tragicus, Exagoge 7-40, 50-54 (Excerpts)

[5348

Mark I 7-9, 16-18

[5345